Warning Against the Use of Anti-Inflammatory Medicines to Cure COVID-19: Building Castles in the Air.
作者信息
Varrassi Giustino
机构信息
Paolo Procacci Foundation, via Tacito 7, 00193, Rome, Italy.
出版信息
Adv Ther. 2020 May;37(5):1705-1707. doi: 10.1007/s12325-020-01321-1. Epub 2020 Apr 1.
Abstract
摘要
相似文献
1
Warning Against the Use of Anti-Inflammatory Medicines to Cure COVID-19: Building Castles in the Air.警告：切勿使用抗炎药物治疗新冠病毒病：此举无异于空中楼阁。
Adv Ther. 2020 May;37(5):1705-1707. doi: 10.1007/s12325-020-01321-1. Epub 2020 Apr 1.
2
NSAIDs for analgesia in the era of COVID-19.COVID-19 疫情时期的 NSAIDs 类药物用于镇痛。
Reg Anesth Pain Med. 2020 Sep;45(9):677-678. doi: 10.1136/rapm-2020-101584. Epub 2020 Jun 3.
3
Could patients taking isotretinoin therapy be immune against SARS-CoV-2?正在接受异维甲酸治疗的患者对SARS-CoV-2有免疫力吗？
Dermatol Ther. 2020 Jul;33(4):e13573. doi: 10.1111/dth.13573. Epub 2020 May 29.
4
Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis.年龄而非性别可能解释动脉高血压和糖尿病对新冠病毒疾病预后的负面影响。
J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.05.010. Epub 2020 May 11.
5
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新冠病毒病风险？
Lancet Respir Med. 2020 May;8(5):e30-e31. doi: 10.1016/S2213-2600(20)30153-3. Epub 2020 Mar 26.
6
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新型冠状病毒肺炎风险？
Lancet Respir Med. 2020 May;8(5):e29. doi: 10.1016/S2213-2600(20)30156-9. Epub 2020 Mar 26.
7
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新型冠状病毒肺炎风险？
Lancet Respir Med. 2020 May;8(5):e28. doi: 10.1016/S2213-2600(20)30158-2. Epub 2020 Mar 26.
8
Speculation is not evidence: antihypertensive therapy and COVID-19.推测并非证据：抗高血压治疗与新型冠状病毒肺炎
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):133-134. doi: 10.1093/ehjcvp/pvaa021.
9
Antihypertensive drugs and risk of COVID-19? - Authors' reply.抗高血压药物与2019冠状病毒病风险？——作者回复
Lancet Respir Med. 2020 May;8(5):e32-e33. doi: 10.1016/S2213-2600(20)30159-4. Epub 2020 Mar 26.
10
Management of diabetes in patients with COVID-19.2019冠状病毒病患者的糖尿病管理
Lancet Diabetes Endocrinol. 2020 Aug;8(8):667-668. doi: 10.1016/S2213-8587(20)30227-8.
引用本文的文献
1
Efficacy and safety profile of corticosteroids and non-steroidal anti-inflammatory drugs in COVID-19 management: A narrative review.皮质类固醇和非甾体抗炎药在新冠病毒疾病管理中的疗效和安全性概况：一项叙述性综述
Front Pharmacol. 2022 Dec 1;13:1063246. doi: 10.3389/fphar.2022.1063246. eCollection 2022.
2
Impact of COVID-19 on chronic pain structures: data from French national survey.COVID-19 对慢性疼痛结构的影响：来自法国全国性调查的数据。
J Comp Eff Res. 2022 Jun;11(9):649-658. doi: 10.2217/cer-2022-0003. Epub 2022 May 5.
3
Pain Management and COVID-19: A Latin American Perspective.疼痛管理与新冠疫情：拉丁美洲视角
Cureus. 2022 Mar 12;14(3):e23100. doi: 10.7759/cureus.23100. eCollection 2022 Mar.
4
Updates on Palliative Medicine in the COVID-19 Era.新冠疫情时代姑息医学的进展
J Clin Med. 2022 Jan 9;11(2):315. doi: 10.3390/jcm11020315.
5
Analgesic Drugs and COVID-19.镇痛药与新型冠状病毒肺炎
J Clin Med. 2021 Feb 2;10(3):545. doi: 10.3390/jcm10030545.
6
Healthcare at the time of COVID-19: A review of the current situation with emphasis on anesthesia providers.COVID-19 时期的医疗保健：当前形势综述，重点关注麻醉师。
Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):539-551. doi: 10.1016/j.bpa.2020.07.002. Epub 2020 Jul 17.
7
Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review.秋水仙碱作为治疗新冠病毒肺炎心血管并发症的潜在药物：一项探索性综述
SN Compr Clin Med. 2020;2(9):1419-1429. doi: 10.1007/s42399-020-00421-x. Epub 2020 Aug 4.
8
The Current Clinically Relevant Findings on COVID-19 Pandemic.关于新冠疫情当前具有临床相关性的发现。
Anesth Pain Med. 2020 Apr 25;10(2):e103819. doi: 10.5812/aapm.103819. eCollection 2020 Apr.
9
The concern about ACE/ARB and COVID-19: Time to hold your horses!关于 ACE/ARB 与 COVID-19 的担忧：是时候冷静下来了！
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):e88-e90. doi: 10.1016/j.japh.2020.06.026. Epub 2020 Jul 31.
10
NSAIDs for analgesia in the era of COVID-19.COVID-19 疫情时期的 NSAIDs 类药物用于镇痛。
Reg Anesth Pain Med. 2020 Sep;45(9):677-678. doi: 10.1136/rapm-2020-101584. Epub 2020 Jun 3.
本文引用的文献
1
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study.中国小气道功能障碍的患病率及其危险因素，以及与吸烟的关系：一项全国性横断面研究的结果。
Lancet Respir Med. 2020 Nov;8(11):1081-1093. doi: 10.1016/S2213-2600(20)30155-7. Epub 2020 Jun 26.
2
Antihypertensive drugs and risk of COVID-19? - Authors' reply.抗高血压药物与2019冠状病毒病风险？——作者回复
Lancet Respir Med. 2020 May;8(5):e32-e33. doi: 10.1016/S2213-2600(20)30159-4. Epub 2020 Mar 26.
3
Clinical Characteristics of Covid-19 in China. Reply.中国新冠病毒肺炎的临床特征。回复
N Engl J Med. 2020 May 7;382(19):1861-1862. doi: 10.1056/NEJMc2005203. Epub 2020 Mar 27.
Zotero 插件